Early reduction in proteinuria is a key predictor of improved long-term kidney health in lupus nephritis (LN). In this episode, Dr. Anna Wolska from the Lupus Foundation of America speaks with Drs. Maria Dall'Era and Anca Askanase about a new propensity analysis comparing voclosporin-based triple immunosuppressive therapy to traditional high-dose glucocorticoid regimens. They discuss findings from the AURA-LV and AURORA 1 studies, highlighting the safety benefits and earlier proteinuria reduction seen with voclosporin. Tune in to explore how these insights may shape LN treatment guidelines and improve patient outcomes. Read the paper published in LSM: https://doi.org/10.1136/lupus-2024-001319
Early reduction in proteinuria is a key predictor of improved long-term kidney health in lupus nephritis (LN). In this episode, Dr. Anna Wolska from the Lupus Foundation of America speaks with Drs. Maria Dall'Era and Anca Askanase about a new propensity analysis comparing voclosporin-based triple immunosuppressive therapy to traditional high-dose glucocorticoid regimens. They discuss findings from the AURA-LV and AURORA 1 studies, highlighting the safety benefits and earlier proteinuria reduction seen with voclosporin. Tune in to explore how these insights may shape LN treatment guidelines and improve patient outcomes.
Read the paper published in LSM: https://doi.org/10.1136/lupus-2024-001319